

# Histological response dynamics in gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue after *Helicobacter pylori* eradication: a single-center longitudinal analysis

## Authors

Vincent Sunder-Plassmann,<sup>1,2</sup> Barbara Kieseewetter,<sup>1</sup> Ingrid Simonitsch-Klupp,<sup>3</sup> Rosa Brand,<sup>3</sup> Werner Dolak,<sup>4</sup> Marius E. Mayerhoefer<sup>5,6</sup> and Markus Raderer<sup>1</sup>

<sup>1</sup>Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria; <sup>3</sup>Department of Pathology, Medical University of Vienna, Vienna, Austria; <sup>4</sup>Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; <sup>5</sup>Department of Radiology, Division of Oncologic Imaging, NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA and <sup>6</sup>Department

of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria

Correspondence:

M. RADERER - markus.raderer@meduniwien.ac.at

<https://doi.org/10.3324/haematol.2025.300054>

Received: October 14, 2025.

Accepted: February 25, 2026.

Early view: March 19, 2026.

©2026 Ferrata Storti Foundation


Published under a CC BY-NC license 

## Supplementary Files

Supplementary Table 1. HP-positive vs HP-negative patients

Characteristics	All patients	HP+	HP-	HP+ vs. HP-
Total cohort, n (%)	111 (100)	75/109 (68.8)	34/109 (31.2)	NA
Median age, years (range)	61.8 (31.5 – 84.6)	63.2 (31.5 – 84.6)	61.0 (35.2 – 84.3)	p > 0.05
Sex, n (%)				
Female	55/111 (49.6)	37/75 (49.3)	16/34 (47.1)	p > 0.05
Male	56/111 (50.4)	38/75 (50.7)	18/34 (52.9)	
Stage (Lugano), n (%)				
I	82/109 (75.2)	58/75 (77.3)	21/34 (61.8)	
II	19/109 (17.4)	11/75 (14.7)	8/34 (23.5)	p > 0.05
IV	8/109 (7.3)	5/75 (6.7)	4/34 (11.8)	
NA	2/111 (1.8)	1/75 (1.3)	1/34 (2.9)	
First-line HP eradication, n (%)	111/111 (100)	75/75 (100)	34/34 (100)	
Median number of cycles, n (range)	1 (1-4)	1 (1-4)	1 (1-4)	p > 0.05
≥ 2 cycles of HP eradication, n (%)	21/111 (18.9)	13/75 (17.3)	8/34 (23.5)	
Autoimmune disease, n (%)	17/111 (15.3)	9/75 (12.0)	8/34 (23.5)	p > 0.05
t11;18)(Q21;q21), n (%)				
positive	21/57 (36.8)	12/34 (35.3)	9/23 (39.1)	
negative	36/57 (63.2)	22/34 (64.7)	14/23 (60.9)	
NA	54/111 (48.7)	41/75 (54.7)	11/34 (32.4)	
Gastritis at diagnosis, n (%)	70/78 (89.7)	51/55 (92.7)	19/23 (82.6)	p > 0.05
NA	33/111 (29.7)	20/75 (26.7)	15/34 (44.1)	
MALT-associated secondary malignancy, n (%)	9/111 (8.1)	7/75 (9.3)	2/34 (5.9)	p > 0.05
DLBCL transformation	7/9 (77.8)	5/75 (6.7)	2/34 (5.9)	p > 0.05
Stomach cancer	2/9 (22.2)	2/75 (2.7)	0/34 (0.0)	p > 0.05
Median follow-up, months (range)	28.9 (1.8 – 202.4)	29.6 (1.81 – 202.4)	27.6 (5.3 – 184.5)	p > 0.05
Median number of follow-ups, n (range)	5 (2 – 22)	5 (2 – 20)	5 (3 – 22)	p > 0.05
Median time between follow-ups, months (range)	5.7 (0.2 – 124.8)	5.9 (0.5 – 124.8)	5.4 (0.2 – 34.2)	p > 0.05
Received further oncological therapy, n (%)	39/111 (35.1)	24/75 (32.0)	15/34 (44.1)	p > 0.05
Best histopathological response, n (%)				
≥ rRD	82/111 (73.9)	62/75 (82.7)	18/34 (52.9)	<b>p = 0.002</b>
≥ pMRD	63/111 (56.8)	47/75 (62.7)	14/34 (41.2)	<b>p = 0.04</b>
CR	52/111 (46.8)	40/75 (53.3)	10/34 (29.4)	<b>p = 0.002</b>
Median time to first response, months (range)				
rRD	5.6 (0 – 124.8)	5.1 (0 – 124.8)	6.2 (1.2 – 40.5)	p > 0.05
pMRD	6.3 (0.8 – 124.8)	5.6 (0.8 – 124.8)	8.7 (1.8 – 40.5)	p > 0.05
CR	9.9 (0.8 – 126.2)	9.6 (0.8 – 126.1)	11.8 (1.8 – 25.2)	p > 0.05

CR, complete remission; DLBCL, diffuse large B-cell lymphoma; HP, helicobacter pylori; n, number; NA, not applicable; NC, no change; pMRD, probable minimal residual disease; rRD, responding residual disease.



**Supplementary Figure 1: Temporal trends in gastric MALT lymphoma patients.** HP, helicobacter pylori; n, number; NA, not available.